Diabetes Blood Tests: Which Labs Are Ordered and What They Mean

What Is Diabetes?

Diabetes mellitus is a group of conditions in which the body cannot properly regulate blood sugar (glucose), either because the pancreas does not produce enough insulin or because the body does not respond to insulin effectively. Type 2 diabetes accounts for about 90–95% of all cases and is strongly linked to weight, physical inactivity, and family history, while type 1 is an autoimmune condition that typically develops in childhood. Blood tests are the primary way to detect diabetes, prediabetes, and gestational diabetes — for a comprehensive overview of the disease itself, see Mayo Clinic’s diabetes guide.

Blood Tests Used to Diagnose and Monitor Diabetes

The following table summarizes the key blood tests associated with diabetes screening, diagnosis, and ongoing monitoring. Ranges may vary slightly by laboratory and individual factors.

Ranges may vary by lab, age, sex, and testing method. Always discuss results with a healthcare provider.

How These Tests Work Together

No single blood test tells the full story of diabetes. Healthcare providers look at multiple tests in combination to make a diagnosis, assess severity, and guide treatment. Each test captures a different piece of the picture.

The A1C test provides a long-term view of blood sugar control over 2–3 months, while the fasting glucose test captures a snapshot at one moment. A person could have a normal fasting glucose but an elevated A1C, which might indicate blood sugar spikes after meals. Conversely, someone with conditions that affect red blood cell lifespan may have a misleading A1C but accurate fasting glucose readings.

The OGTT is especially useful for detecting prediabetes and gestational diabetes because it measures how efficiently the body processes sugar after a controlled glucose load. A fasting insulin test can detect insulin resistance before blood sugar levels rise to abnormal ranges, offering a window for early intervention.

For people already diagnosed with diabetes, additional tests become important. A lipid panel tracks cardiovascular risk, which is elevated in diabetes. Creatinine and eGFR monitor kidney health, since diabetes is the leading cause of chronic kidney disease. The C-peptide test can help distinguish between type 1 and type 2 diabetes and assess how much insulin the pancreas still produces.

Reference Range Visualizations

These visual bars illustrate where the standard diagnostic thresholds fall for two of the most common diabetes screening tests. They reflect the same reference ranges listed in the table above.

These thresholds are based on ADA diagnostic criteria. Actual ranges may vary by laboratory. These visualizations are educational references, not interpretation tools.

How Doctors Interpret Multiple Results Together

In clinical practice, diabetes diagnosis and risk assessment rely on patterns across multiple tests rather than any single value. Healthcare providers evaluate results in context, weighing several factors before reaching conclusions.

Concordant vs. Discordant Results

When both A1C and fasting glucose fall in the borderline range, clinical guidelines generally interpret this as stronger evidence of prediabetes than when only one marker is elevated. Concordant results — where multiple tests point in the same direction — carry more diagnostic weight. When results are discordant (one test borderline, the other normal), healthcare providers typically consider repeating the abnormal test or ordering an additional test such as the OGTT to clarify the picture.

Confirmation With Repeat Testing

Clinical guidelines recommend that a single abnormal result be confirmed with a second test on a different day before a diabetes diagnosis is made, unless symptoms of hyperglycemia are clearly present. This practice accounts for the natural day-to-day variability in blood glucose and reduces the risk of a false-positive diagnosis. In medical practice, this confirmation step is considered standard.

Transient Influences on Results

Healthcare providers recognize that acute illness, physiological stress, recent surgery, or medication changes can temporarily elevate glucose levels without indicating diabetes. Clinical practice accounts for these confounders by considering the timing and circumstances of the test. When results are obtained during an acute illness or hospitalization, providers typically recommend retesting once the patient has recovered.

Companion Panels in Diabetes Screening

In clinical practice, diabetes screening is rarely performed in isolation. Healthcare providers commonly order a lipid panel alongside glucose tests because insulin resistance and cardiovascular risk are closely linked. Kidney function tests (creatinine, eGFR) are also standard because diabetes is the leading cause of chronic kidney disease. This comprehensive approach allows providers to assess overall metabolic health rather than focusing on a single marker.

Test Selection Based on Individual Factors

The choice between A1C and fasting glucose is not always straightforward. Clinical guidelines note that A1C may be unreliable in the presence of hemoglobin variants (such as sickle cell trait), iron deficiency anemia, recent blood transfusion, or pregnancy. In these situations, healthcare providers generally rely on fasting glucose or the OGTT instead. Conversely, A1C may be preferred when fasting is impractical or when a longer-term picture of glucose control is more clinically useful.

Only a healthcare provider who knows your complete medical history can interpret your individual lab results.

Questions to Ask Your Doctor About Your Results

If you have questions about your diabetes-related lab work, these topics may help guide a productive conversation with your healthcare provider.

• “How often should my blood sugar levels be rechecked based on these results?”
• “Would additional tests help clarify the picture?”
• “Could any medications or recent illness have affected these results?”
• “What specific targets should I be working toward?”
• “Are there lifestyle changes that could improve these numbers before the next test?”
• “Should I be monitoring any other health markers given these results?”
• “What would you recommend as a follow-up timeline?”

How Often to Test: Screening and Monitoring Guidelines

Screening for diabetes is recommended for all adults starting at age 35, or earlier for those with risk factors such as being overweight, having a family history of diabetes, or belonging to a higher-risk ethnic group (African American, Hispanic, Native American, Asian American, or Pacific Islander). The American Diabetes Association (ADA) recommends screening every 3 years if results are normal.

For people with prediabetes, testing is recommended at least annually to monitor for progression to diabetes. Lifestyle changes — including moderate weight loss, regular physical activity, and dietary improvements — have been shown to reduce progression risk by up to 58%.

For people managing type 1 or type 2 diabetes, A1C is typically tested every 3–6 months depending on blood sugar stability. A comprehensive metabolic panel and lipid panel are usually ordered at least once a year. Kidney function (creatinine, eGFR, and urine albumin) is monitored annually or more often if kidney damage is detected.

Gestational diabetes screening typically occurs between 24 and 28 weeks of pregnancy using a glucose challenge test or OGTT. Women who had gestational diabetes are recommended to be tested for type 2 diabetes 4–12 weeks after delivery and every 1–3 years thereafter.

Frequently Asked Questions

Medical Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
• Mayo Clinic. Diabetes — Diagnosis and Treatment.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes Tests & Diagnosis.
• Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report.
• MedlinePlus. Diabetes. U.S. National Library of Medicine.

Related Panels and Biomarkers